Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer's disease: a focus on aducanumab and lecanemab
M Shi, F Chu, F Zhu, J Zhu - Frontiers in aging neuroscience, 2022 - frontiersin.org
Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world,
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …
and its main pathological features consist of amyloid-β (Aβ) plaque deposits and …
Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches
D Kellar, S Craft - The Lancet Neurology, 2020 - thelancet.com
Insulin is a peptide secreted by the pancreas and plays an important role in the regulation of
glucose metabolism in peripheral tissues. Although the role of insulin in the periphery is well …
glucose metabolism in peripheral tissues. Although the role of insulin in the periphery is well …
The role of NMDA receptors in Alzheimer's disease
J Liu, L Chang, Y Song, H Li, Y Wu - Frontiers in neuroscience, 2019 - frontiersin.org
In Alzheimer's disease (AD), early synaptic dysfunction is associated with the increased
oligomeric amyloid-beta peptide, which causes NMDAR-dependent synaptic depression …
oligomeric amyloid-beta peptide, which causes NMDAR-dependent synaptic depression …
Implications of sleep disturbance and inflammation for Alzheimer's disease dementia
Nearly half of all adults older than 60 years of age report sleep disturbance, as characterised
either by reports of insomnia complaints with daytime consequences, dissatisfaction with …
either by reports of insomnia complaints with daytime consequences, dissatisfaction with …
[HTML][HTML] Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression
Alzheimer's disease (AD) displays a long asymptomatic stage before dementia. We
characterize AD stage-associated molecular networks by profiling 14,513 proteins and …
characterize AD stage-associated molecular networks by profiling 14,513 proteins and …
New insights into the pathogenesis of Alzheimer's disease
L Fan, C Mao, X Hu, S Zhang, Z Yang, Z Hu… - Frontiers in …, 2020 - frontiersin.org
Alzheimer's disease (AD), a common neurodegenerative disease in the elderly and the most
prevalent cause of dementia, is characterized by progressive cognitive impairment. The …
prevalent cause of dementia, is characterized by progressive cognitive impairment. The …
Drug candidates in clinical trials for Alzheimer's disease
SY Hung, WM Fu - Journal of biomedical science, 2017 - Springer
Alzheimer's disease (AD) is a major form of senile dementia, characterized by progressive
memory and neuronal loss combined with cognitive impairment. AD is the most common …
memory and neuronal loss combined with cognitive impairment. AD is the most common …
A review on advances of treatment modalities for Alzheimer's disease
Alzheimer's disease (AD) is a multifactorial neurodegenerative disease which is mainly
characterized by progressive impairment in cognition, emotion, language and memory in …
characterized by progressive impairment in cognition, emotion, language and memory in …
Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions
A Abeysinghe, R Deshapriya, C Udawatte - Life sciences, 2020 - Elsevier
Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most
common cause for dementia. Despite huge global economic burden and the impact on the …
common cause for dementia. Despite huge global economic burden and the impact on the …
A perspective on multi-target drugs for Alzheimer's disease
O Benek, J Korabecny, O Soukup - Trends in pharmacological sciences, 2020 - cell.com
Alzheimer's disease (AD) has a complex pathophysiology that includes aggregation of
pathological proteins, impaired neurotransmission, increased oxidative stress, or microglia …
pathological proteins, impaired neurotransmission, increased oxidative stress, or microglia …